Clinical Research Navigator: An Interactive Decision-Making Tool

Decision Assistant — Lesson 2 (Obs/Interventional/Translational)

Lesson 2 Decision Assistant

2.1 Observational • 2.2 Interventional • 2.3 Translational — structured, interactive planning

How to use this tool

  1. Observational Designer: Pick study type → get bias controls, sampling & analysis suggestions.
  2. Interventional Designer: Configure randomization, blinding & control → get trial skeleton & governance.
  3. Translational Roadmap: Map work across T0–T4 with gating deliverables.
  4. Outputs: Copy/print/export JSON for your notes or protocol synopsis.
  5. Scenarios: Prefill with solved examples to learn fast.
Note: Educational planning aid — align with sponsor SOPs, IRB/IEC, and local regulations.

Lesson goals

  • Differentiate cohort, case-control, cross-sectional designs
  • Plan RCTs, single-arm, crossover, factorial trials
  • Bridge lab-to-clinic with T0–T4 translational milestones
Bias controlsConfoundingRandomization BlindingEndpointsGovernance

Observational Studies Designer (Lesson 2.1)

Design & Analysis Guidance

Fill inputs and click Build Plan.
What counts as observational?

No investigator-assigned intervention. Data may be prospective (follow-up) or retrospective (records). You estimate associations, not causality.

Interventional Studies Designer (Lesson 2.2)

Trial Skeleton & Governance

Configure and click Build Trial Skeleton.
Quick reminders
  • Randomization reduces selection bias; stratify on strong prognostic factors.
  • Blinding reduces performance/assessment bias; if open-label, use objective endpoints and blinded adjudication.
  • Register before first participant; pre-specify SAP and interims.

Translational Research Roadmap (Lesson 2.3)

Milestones, Gating Criteria & Risks

Pick a stage and click Map Milestones.
Why translational?

It connects lab discoveries to clinical impact via staged evidence and governance, ensuring relevance, safety, and feasibility.

Load Example Scenarios

Obs — High sugar & Type 2 Diabetes (Cross-sectional)

FFQ + glucose; logistic regression adjusting for age, BMI, activity, family history; stratified sampling.

RCT — Cholesterol Supplement vs Placebo

Double-blind, 1:1 block randomization; primary Δ LDL-C at 24w; ITT + ANCOVA.

Translational — Breast Cancer Diagnostic (T0→T4)

Biomarker discovery → assay validation → Ph I/II accuracy → Ph III implementation → RWE.

Cohort — Smoking & Lung Cancer

Prospective cohort; incident cancer; Cox model; careful loss-to-follow-up controls.

Outputs

Consolidated Plan

Build any section to populate this area.

Summary Tables

Observational Studies (Lesson 2.1)
CategoryDetailsExamples
DefinitionObserve outcomes without manipulating environment; natural settings.Community BP prevalence survey.
Types1) Cohort 2) Case-control 3) Cross-sectionalSmoking→lung CA; pesticide→Parkinson’s; obesity prevalence
MethodologiesData collection, sampling, analysis w/ confounder controlPROs/records; stratified sampling; logistic regression
AdvantagesMultiple outcomes/exposures; cheaper; rare conditions; long-termLarge lifestyle cohorts
LimitationsAssociations only; bias; confoundingDiet & cancer confounded by genetics/behavior
Interventional Studies (Lesson 2.2)
CategoryDetailsExamples
DefinitionActive intervention to test effects on outcomesDrug vs placebo
TypesRCT, Single-arm, Crossover, FactorialHypertension RCT; gene therapy; pain crossover; diet×exercise factorial
MethodologiesRandomization, blinding, control groupsComputer sequence; double-blind; SOC control
AdvantagesCan establish causality; control confounding; robust dataVaccine efficacy RCTs
LimitationsExpensive; ethics; generalizability gapsLong oncology trials
Translational Research (Lesson 2.3)
CategoryDetailsExamples
DefinitionBridge lab discoveries to clinical applicationBench→therapy/diagnostics
PhasesT0,T1,T2,T3,T4Biomarkers→preclinical→Ph I/II→Ph III→RWE
MethodologiesInterdisciplinary, regulatory/ethics, patient involvementTeam science, FDA/EMA, advocacy groups
AdvantagesAccelerates impact; increases relevance; fosters innovationRapid COVID-19 vaccine development
LimitationsResource-intensive; complex coordination; regulatory hurdlesCostly oncology translation